Skip to main content
. 2021 Oct 31;39(1):314–327. doi: 10.1007/s12325-021-01960-y

Table 1.

Patient demographics

Characteristics Total (n = 17,881) Treatment post-index event
Untreated with LLT 6 months post-index event (n = 1096) Moderate-/low-intensity LLT (n = 8863) High-intensity LLT (n = 7922)
Age years, mean (SD) 67.1 (9.8) 70.9 (8.3) 68.5 (9.1) 65.0 (10.3)
Male, n (%) 12,780 (71.5) 705 (64.3) 6069 (68.5) 6006 (75.8)
Comorbidities, pre-index, n (%)
 ACS 10,063 (56.3) 356 (32.5) 3574 (40.3) 6133 (77.4)
 IS 4053 (22.7) 395 (36.0) 2989 (33.7) 669 (8.4)
 PAD 3765 (21.1) 345 (31.5) 2300 (26.0) 1120 (14.1)
 Diabetes 4368 (24.4) 372 (33.9) 2154 (24.3) 1842 (23.3)
 Lipid metabolism disturbances 5872 (32.8) 164 (15.0) 2525 (28.5) 3183 (40.2)
 Obesity 987 (5.5) 37 (3.4) 352 (4.0) 598 (7.5)
 Hypertension 9014 (50.4) 481 (43.9) 4453 (50.2) 4080 (51.5)
 Previous myocardial infarction 7877 (44.1) 253 (23.1) 2407 (27.2) 5217 (65.9)
 Other forms of ischemic heart disease 9298 (52.0) 405 (37.0) 3865 (43.6) 5028 (63.5)
 Heart failure 2686 (15.0) 253 (23.1) 1259 (14.2) 1174 (14.8)
 Cerebrovascular disease 4469 (25.0) 415 (37.9) 2968 (33.5) 1086 (13.7)
 Chronic renal disease 1476 (8.3) 209 (19.1) 746 (8.4) 521 (6.6)
 Previous coronary artery bypass graft 2636 (14.7) 95 (8.7) 1075 (12.1) 1466 (18.5)
 Previous coronary angioplasty 7085 (39.6) 129 (11.8) 2278 (25.7) 4678 (59.1)
 Cerebral revascularization procedures 1260 (7.0) 73 (6.7) 860 (9.7) 327 (4.1)
 Antihypertensive medications at index 3957 (22.1) 226 (20.6) 2114 (23.9) 1617 (20.4)
 Anti-diabetic medications at index 639 (3.6) 54 (4.9) 390 (4.4) 195 (2.5)
 Anti-thrombotic medications at index 15,179 (84.9) 612 (55.8) 7508 (84.7) 7059 (89.1)

LDL-C and HDL-C measurements at index event were not available

ACS acute coronary syndrome, HDL-C high-density lipoprotein cholesterol, IS ischemic stroke/transient ischemic attack, LDL-C low-density lipoprotein cholesterol, LLT lipid-lowering therapy, PAD peripheral artery disease, SD standard deviation